Drägerwerk confirms its 2026 outlook and Drägerwerk stock costs EUR 102.10

Drägerwerk confirms its 2026 outlook after reporting third-quarter EBIT of EUR 48.00 million, down from EUR 56.70 million a year earlier. The preliminary figures were published on October 14, 2026, in an issuer release carried by WebDisclosure.

Revenue grew as EBIT fell

Drägerwerk's third-quarter revenue rose 2.10 percent to EUR 851.00 million from EUR 833.30 million in the third quarter of 2025, according to the same issuer release. The EBIT margin fell to 5.60 percent from 6.80 percent, and the result included EUR 20.10 million in customs-duty refunds.

The figures show a sharper split between demand and earnings conversion. Order intake increased 8.20 percent to EUR 926.00 million from EUR 856.10 million, while the Safety Technology division lifted revenue 5.30 percent to EUR 381.00 million. Medical Technology revenue declined 0.40 percent to EUR 469.00 million.

What does the outlook mean for margins?

Drägerwerk kept its currency-adjusted 2026 revenue-growth forecast at 2.00 to 6.00 percent and its EBIT-margin range at 6.00 to 8.00 percent. The company said higher functional expenses offset the stronger sales performance in the third quarter. For investors, the next test is whether order growth converts into operating profit without relying on customs refunds.

Stock remains below the Xetra close

Drägerwerk stock was trading at EUR 102.10 at Lang & Schwarz on October 27, 2026, at 9:15 a.m. CET, down 0.29 percent versus the Xetra close of October 26, 2026, at EUR 102.40. The quote is below the 52-week high of EUR 125.40 and above the 52-week low of EUR 66.00.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.

Market context: Market report DAX.

More news and analyses on Drägerwerk stock